title: Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML.
abstract: We retrospectively assessed whether normalized bone marrow WT1 levels could be used for risk stratification in a consecutive series of 584 acute myeloid leukemia (AML) patients. A cutoff value of 5065 copies at diagnosis identified two prognostic groups (overall survival (OS): 44 ± 3 vs 36 ± 3%, P=0.023; leukemia-free survival (LFS): 47 ± 3 vs 36 ± 4%, P=0.038; and cumulative incidence of relapse (CIR): 37 ± 3 vs 47 ± 4%, P=:0.043). Three groups were identified on the basis of WT1 levels post-induction: Group 0 (WT1 between 0 and 17.5 copies, 134 patients, OS: 59 ± 4%, LFS:59 ± 4% and CIR: 26 ± 4%); Group 1 (WT1 between 17.6 and 170.5 copies, 160 patients, OS: 48 ± 5%, LFS:41 ± 4% and CIR: 45 ± 4%); and Group 2 (WT1 >170.5 copies, 71 patients, OS: 23 ± 6%, LFS: 19 ± 7% and CIR: 68 ± 8%) (P<0.001). Post-intensification samples distinguished three groups: patients with WT1 >100 copies (47 patients, 16%); an intermediate group of patients with WT1 between 10 and 100 copies (148 patients, 52%); and a third group with WT1 <10 copies (92 patients, 32%). Outcomes differed significantly in terms of OS (30 ± 7%, 59 ± 4%, 72 ± 5%), LFS (24 ± 7%, 46 ± 4%, 65 ± 5%) and relapse probability (CIR 72 ± 7%, 45 ± 4%, 25 ± 5%), all P<0.001. WT1 levels in bone marrow assayed using the standardized ELN method provide relevant prognostic information in de novo AML.
authors.affiliation: Laboratori \[dacute]Hematologia, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: J F
authors.initials: JF
authors.lastname: Nomdedéu
authors.forename: M
authors.initials: M
authors.lastname: Hoyos
authors.forename: M
authors.initials: M
authors.lastname: Carricondo
authors.forename: E
authors.initials: E
authors.lastname: Bussaglia
authors.forename: C
authors.initials: C
authors.lastname: Estivill
authors.forename: J
authors.initials: J
authors.lastname: Esteve
authors.forename: M
authors.initials: M
authors.lastname: Tormo
authors.forename: R
authors.initials: R
authors.lastname: Duarte
authors.forename: O
authors.initials: O
authors.lastname: Salamero
authors.forename: M P Q
authors.initials: MP
authors.lastname: de Llano
authors.forename: A
authors.initials: A
authors.lastname: García
authors.forename: J
authors.initials: J
authors.lastname: Bargay
authors.forename: I
authors.initials: I
authors.lastname: Heras
authors.forename: J M
authors.initials: JM
authors.lastname: Martí-Tutusaus
authors.forename: A
authors.initials: A
authors.lastname: Llorente
authors.forename: J M
authors.initials: JM
authors.lastname: Ribera
authors.forename: D
authors.initials: D
authors.lastname: Gallardo
authors.forename: A
authors.initials: A
authors.lastname: Aventin
authors.forename: S
authors.initials: S
authors.lastname: Brunet
authors.forename: J
authors.initials: J
authors.lastname: Sierra
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D001853:Bone Marrow / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D060830:Consolidation Chemotherapy; D005260:Female; D005500:Follow-Up Studies; D018628:Gene Dosage; D006801:Humans; D016130:Immunophenotyping; D015470:Leukemia, Myeloid, Acute; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D016133:Polymerase Chain Reaction; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D025721:WT1 Proteins / Q000235:genetics* / Q000378:metabolism; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D025721:WT1 Proteins; C583751:WT1 protein, human